Literature DB >> 18417033

The potential of RNA interference-based therapies for viral infections.

Diana D Huang1.   

Abstract

RNA interference (RNAi) is a natural mechanism in cells that suppresses or silences the expression of aberrant or foreign genes. This activity is being developed as a potential antiviral therapeutic strategy. Studies in vitro, and some in vivo, appear to show the feasibility of using RNAi to treat virus infection. Therapeutic use of RNAi seems to be promising when directed against viruses that cause localized acute infections in accessible target cells. Therapeutic strategies using RNAi against viruses that cause chronic infections, such as HIV, hepatitis B virus, or hepatitis C virus, are more difficult to design, but studies have begun to address identifiable problems. Two clinical trials using RNAi have recently been initiated--one phase II trial against respiratory syncytial virus and a phase I trial against HIV. It will be of much interest to see whether nucleic acid therapies can offer another route to treating viral infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417033      PMCID: PMC7088822          DOI: 10.1007/s11904-008-0006-4

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  46 in total

1.  Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo.

Authors:  X-Y Niu; Z-L Peng; W-Q Duan; H Wang; P Wang
Journal:  Int J Gynecol Cancer       Date:  2006 Mar-Apr       Impact factor: 3.437

2.  Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro.

Authors:  Marjorie A Robbins; Mingjie Li; Irene Leung; Haitang Li; Doris V Boyer; Yong Song; Mark A Behlke; John J Rossi
Journal:  Nat Biotechnol       Date:  2006-04-30       Impact factor: 54.908

3.  Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing.

Authors:  Yamina Bennasser; Shu-Yun Le; Monsef Benkirane; Kuan-Teh Jeang
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

4.  Hepatitis B virus is inhibited by RNA interference in cell culture and in mice.

Authors:  Ruo-Su Ying; Cai Zhu; Xue-Gong Fan; Ning Li; Xue-Fei Tian; Hong-Bo Liu; Bao-Xin Zhang
Journal:  Antiviral Res       Date:  2006-06-28       Impact factor: 5.970

5.  Inhibition of influenza virus production in virus-infected mice by RNA interference.

Authors:  Qing Ge; Lily Filip; Ailin Bai; Tam Nguyen; Herman N Eisen; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

6.  Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients.

Authors:  Rafael G Amado; Ronald T Mitsuyasu; Joseph D Rosenblatt; Frances K Ngok; Andreas Bakker; Steve Cole; Nathalie Chorn; Lii-Shin Lin; Gregory Bristol; Maureen P Boyd; Janet L MacPherson; Gregory C Fanning; Alison V Todd; Julie A Ely; Jerome A Zack; Geoff P Symonds
Journal:  Hum Gene Ther       Date:  2004-03       Impact factor: 5.695

7.  HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome.

Authors:  Ellen M Westerhout; Marcel Ooms; Monique Vink; Atze T Das; Ben Berkhout
Journal:  Nucleic Acids Res       Date:  2005-02-01       Impact factor: 16.971

8.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque.

Authors:  Bao-jian Li; Qingquan Tang; Du Cheng; Chuan Qin; Frank Y Xie; Qiang Wei; Jun Xu; Yijia Liu; Bo-jian Zheng; Martin C Woodle; Nanshan Zhong; Patrick Y Lu
Journal:  Nat Med       Date:  2005-08-21       Impact factor: 53.440

9.  Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region.

Authors:  Joyce A Wilson; Christopher D Richardson
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more
  8 in total

1.  Suppression of lung cancer metastasis-related protein 1 (LCMR1) inhibits the growth of colorectal cancer cells.

Authors:  E Ji-Fu; Jun-Jie Xing; Li-Qiang Hao; Chuan-Gang Fu
Journal:  Mol Biol Rep       Date:  2011-07-06       Impact factor: 2.316

2.  Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence.

Authors:  David A Stein; Stuart T Perry; Michael D Buck; Christopher S Oehmen; Matthew A Fischer; Elizabeth Poore; Jessica L Smith; Alissa M Lancaster; Alec J Hirsch; Mark K Slifka; Jay A Nelson; Sujan Shresta; Klaus Früh
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

3.  MicroRNA-21 protects neurons from ischemic death.

Authors:  Ben Buller; Xianshuang Liu; Xinli Wang; Rui L Zhang; Li Zhang; Ann Hozeska-Solgot; Michael Chopp; Zheng G Zhang
Journal:  FEBS J       Date:  2010-09-14       Impact factor: 5.542

4.  Senecavirus A Enhances Its Adaptive Evolution via Synonymous Codon Bias Evolution.

Authors:  Simiao Zhao; Huiqi Cui; Zhenru Hu; Li Du; Xuhua Ran; Xiaobo Wen
Journal:  Viruses       Date:  2022-05-16       Impact factor: 5.818

5.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

Review 6.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

7.  Reduced Dicer expression in the cord blood of infants admitted with severe respiratory syncytial virus disease.

Authors:  Christopher S Inchley; Tonje Sonerud; Hans O Fjærli; Britt Nakstad
Journal:  BMC Infect Dis       Date:  2011-03-08       Impact factor: 3.090

8.  Cellular protein GLTSCR2: A valuable target for the development of broad-spectrum antivirals.

Authors:  Cui-Cui Li; Hui-Jun Dong; Peng Wang; Wen Meng; Xiao-Jing Chi; Shi-Chong Han; Shuo Ning; Chuang Wang; Xiao-Jia Wang
Journal:  Antiviral Res       Date:  2017-03-07       Impact factor: 5.970

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.